SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India

Microorganisms - Tập 9 Số 7 - Trang 1542
Sarah Cherian1, Varsha Potdar1, Santosh Jadhav1, Pragya D. Yadav1, Nivedita Gupta2, Mousumi Das1, Partha Rakshit3, Sujeet Kumar Singh3, Priya Abraham1, Samiran Panda2, NIC Team
1ICMR-National Institute of Virology, Pune 411001, India
2Indian Council of Medical Research, New Delhi, 110029, India
3National Centre for Disease Control, New Delhi 110054, India

Tóm tắt

As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being used to investigate its transmission and evolution. Against the backdrop of the global emergence of “variants of concern” (VOCs) during December 2020 and an upsurge in a state in the western part of India since January 2021, whole genome sequencing and analysis of spike protein mutations using sequence and structural approaches were undertaken to identify possible new variants and gauge the fitness of the current circulating strains. Phylogenetic analysis revealed that newly identified lineages B.1.617.1 and B.1.617.2 were predominantly circulating. The signature mutations possessed by these strains were L452R, T478K, E484Q, D614G and P681R in the spike protein, including within the receptor-binding domain (RBD). Of these, the mutations at residue positions 452, 484 and 681 have been reported in other globally circulating lineages. The structural analysis of RBD mutations L452R, T478K and E484Q revealed that these may possibly result in increased ACE2 binding while P681R in the furin cleavage site could increase the rate of S1-S2 cleavage, resulting in better transmissibility. The two RBD mutations, L452R and E484Q, indicated decreased binding to select monoclonal antibodies (mAbs) and may affect their neutralization potential. Further in vitro/in vivo studies would help confirm the phenotypic changes of the mutant strains. Overall, the study revealed that the newly emerged variants were responsible for the second wave of COVID-19 in Maharashtra. Lineage B.1.617.2 has been designated as a VOC delta and B.1.617.1 as a variant of interest kappa, and they are being widely reported in the rest of the country as well as globally. Continuous monitoring of these and emerging variants in India is essential.

Từ khóa


Tài liệu tham khảo

Shang, 2020, Structural basis of receptor recognition by SARS-CoV-2, Nature, 581, 221, 10.1038/s41586-020-2179-y

Wan, 2020, Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus, J. Virol., 94, e00127-20, 10.1128/JVI.00127-20

Elbe, 2017, Data, disease and diplomacy: GISAID’s innovative contribution to global health, Glob. Chall., 1, 33, 10.1002/gch2.1018

Korber, 2020, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell, 182, 812, 10.1016/j.cell.2020.06.043

Volz, 2021, Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity, Cell, 184, 64, 10.1016/j.cell.2020.11.020

World Health Organization (2021, June 12). Tracking SARS-CoV-2 Variants. Available online: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

Leung, 2021, Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020, Eurosurveillance, 26, 2002106, 10.2807/1560-7917.ES.2020.26.1.2002106

Rambaut, 2020, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology, Nat. Microbiol., 5, 1403, 10.1038/s41564-020-0770-5

Potdar, 2021, Phylogenetic classification of the whole-genome sequences of SARS-CoV-2 from India & evolutionary trends, Indian J. Med. Res., 153, 166, 10.4103/ijmr.IJMR_3418_20

Shepard, S.S., Meno, S., Bahl, J., Wilson, M.M., Barnes, J., and Neuhaus, E. (2016). Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genom., 17.

Yadav, 2020, Full-genome sequences of the first two SARS-CoV-2 viruses from India, Indian J. Med. Res., 151, 200, 10.4103/ijmr.IJMR_1029_20

Katoh, 2002, MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform, Nucleic Acids Res., 30, 3059, 10.1093/nar/gkf436

Tamura, 2013, MEGA6: Molecular evolutionary genetics analysis version 6.0, Mol. Biol. Evol., 30, 2725, 10.1093/molbev/mst197

Benton, 2020, Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion, Nature, 588, 327, 10.1038/s41586-020-2772-0

Wang, 2020, Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2, Cell, 181, 894, 10.1016/j.cell.2020.03.045

Hansen, 2020, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, Am. Assoc. Adv. Sci., 369, 1010

Ju, 2020, Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature, 584, 115, 10.1038/s41586-020-2380-z

Greaney, 2021, Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies, Cell Host Microbe., 29, 463, 10.1016/j.chom.2021.02.003

Lam, 2021, Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, Cell, 184, 2372, 10.1016/j.cell.2021.03.013

Yadav, P.D., Nyayanit, D.A., Majumdar, T., Patil, S., Kaur, H., Gupta, N., Shete, A.M., Pandit, P., Kumar, A., and Aggarwal, N. (2021). An Epidemiological Analysis of SARS-CoV-2 Genomic Sequencesfrom Different Regions of India. Viruses, 13.

Sarkar, 2021, Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: An endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations, Arch. Virol., 166, 801, 10.1007/s00705-020-04911-0

Zeng, 2020, Global analysis of more than 50,000 SARS-CoV-2 genomes reveals epistasis between eight viral genes, Proc. Natl. Acad. Sci. USA, 117, 31519, 10.1073/pnas.2012331117

England, P.H. (2021, June 14). SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 10, Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf.

Tada, T., Zhou, H., Dcosta, B.M., Samanovic, M.I., Mulligan, M.J., and Landau, N.R. (2021). The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv.

McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A.C., Di Iulio, J., Tortorici, M.A., Navarro, M.-J., Silacci-Fregni, C., and Saliba, C. (2021). SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv.

Motozono, C., Toyoda, M., Zahradnik, J., Ikeda, T., Saito, A., Tan, T.S., Ngare, I., Nasser, H., Kimura, I., and Uriu, K. (2021). An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv.

Yadav, P.D., Sapkal, G.N., Abraham, P., Ella, R., Deshpande, G., Patil, D.Y., Nyayanit, D.A., Gupta, N., Sahay, R.R., and Shete, A.M. (2021). Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin. Infect. Dis., ciab411.

Yadav, P.D., Sapkal, G.N., Abraham, P., Deshpande, G., Nyayanit, D.A., Patil, D.Y., Gupta, N., Sahay, R.R., Shete, A.M., and Kumar, S. (2021). Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1. Clin. Infect. Dis., ciab483.

Yadav, P.D., Sapkal, G.N., Ella, R., Sahay, R.R., Nyayanit, D.A., Patil, D.Y., Deshpande, G., Shete, A.M., Gupta, N., and Mohan, V.K. (2021). Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv.

Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, S.S., and Thelwall, S. (2021). Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv.

Li, 2020, The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity, Cell, 182, 1284, 10.1016/j.cell.2020.07.012

Chen, J., Gao, K., Wang, R., and Wei, G.-W. (2021). Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. bioRxiv.

Liu, 2021, Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization, Cell Host Microbe., 29, 477, 10.1016/j.chom.2021.01.014

Deng, 2021, Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant, Cell, 184, 3426, 10.1016/j.cell.2021.04.025

Tchesnokova, V., Kulakesara, H., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., and Deng, K. (2021). Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants. bioRxiv.

Hoffmann, M., Hofmann-Winkler, H., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Sidarovich, A., Moldenhauer, A.-S., Winkler, M.S., and Schulz, S. (2021). SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. bioRxiv.

Di Giacomo, S., Mercatelli, D., Rakhimov, A., and Giorgi, F.M. (2021). Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J. Med. Virol.

Thông tin
Thông tin xuất bản

Microorganisms

Tập 9 Số 7

1542

Thông tin tác giả